MARKET

PACB

PACB

PacBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.44
+1.85
+6.71%
After Hours: 28.88 -0.56 -1.90% 19:58 09/17 EDT
OPEN
27.92
PREV CLOSE
27.59
HIGH
29.53
LOW
27.61
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
53.69
52 WEEK LOW
7.56
MARKET CAP
5.86B
P/E (TTM)
-63.3391
1D
5D
1M
3M
1Y
5Y
Pacific Biosciences Of California Inc (PACB) President & CEO Christian O Henry Sold $2. ...
GuruFocus News · 2d ago
Insider Sell: Pacific Biosciences Of California
MT Newswires · 2d ago
Single Cell Genome Sequencing Market: Product Specification, Share, Size, Emerging Trends, Competitive Analysis and Forecast 2028
Research Nester published a report titled which delivers detailed overview of the global single cell genome sequencingmarket in terms of market segmentation by product, application, end user and by region.
AmericaNewsHour · 4d ago
5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More
Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this happened globally and in the U.S.
Benzinga · 09/06 13:30
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Virtual Healthcare Conference on September...
GlobeNewswire · 09/03 13:00
Pacific Biosciences (PACB) Down 0.1% Since Last Earnings Report: Can It Rebound?
Zacks.com · 09/02 04:32
Pacific Biosciences Wins $664K Contract Titled 'Delivery Order issued under USDA Indefinite Delivery Indefinite Quantity (IDIQ) Contract # 12405B21D0002 with Pacific Biosciences of California'
https://sam.gov/opp/c67143caddf245a4ae4d11611987bd82/view
Benzinga · 08/25 17:09
Here's Why You Should Retain PacBio (PACB) Stock For Now
Zacks.com · 08/23 14:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PACB. Analyze the recent business situations of PacBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PACB stock price target is 45.75 with a high estimate of 62.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 338
Institutional Holdings: 184.63M
% Owned: 92.78%
Shares Outstanding: 199.00M
TypeInstitutionsShares
Increased
94
16.97M
New
46
2.96M
Decreased
70
8.06M
Sold Out
47
3.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.54%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Chairman/Independent Director
John Milligan
President/Chief Executive Officer/Director
Christian Henry
Chief Financial Officer
Susan Kim
Chief Operating Officer
Mark Van Oene
Senior Vice President
Catherine Ball
Senior Vice President
Denis Zaccarin
Chief Accounting Officer
Michele Farmer
Other
Peter Fromen
Director
Kathy Ordonez
Independent Director
David Botstein
Independent Director
William Ericson
Independent Director
Randall Livingston
Independent Director
Marshall Mohr
Independent Director
Lucy Shapiro
No Data
  • All
  • Financials
  • Insiders
More
About PACB
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Webull offers kinds of Pacific Biosciences of California Inc stock information, including NASDAQ:PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PACB stock methods without spending real money on the virtual paper trading platform.